KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis
TSX:GUD - Toronto Stock Exchange - CA4990531069 - Common Stock - Currency: CAD
Overall GUD gets a fundamental rating of 5 out of 10. We evaluated GUD against 33 industry peers in the Pharmaceuticals industry. GUD has an average financial health and profitability rating. GUD is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year GUD was profitable.
In the past year GUD had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: GUD reported negative net income in multiple years.
Of the past 5 years GUD 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.10%, GUD is in the better half of the industry, outperforming 78.79% of the companies in the same industry.
GUD has a better Return On Equity (1.39%) than 78.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.1% | ||
| ROE | 1.39% | ||
| ROIC | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 2.97%, GUD belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
GUD's Profit Margin has declined in the last couple of years.
GUD has a Gross Margin of 44.95%. This is in the better half of the industry: GUD outperforms 66.67% of its industry peers.
GUD's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 2.97% | ||
| GM | 44.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
GUD has less shares outstanding than it did 1 year ago.
GUD has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, GUD has an improved debt to assets ratio.
2.2 Solvency
GUD has an Altman-Z score of 2.68. This is not the best score and indicates that GUD is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.68, GUD belongs to the top of the industry, outperforming 87.88% of the companies in the same industry.
A Debt/Equity ratio of 0.04 indicates that GUD is not too dependend on debt financing.
The Debt to Equity ratio of GUD (0.04) is better than 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.68 |
ROIC/WACCN/A
WACC9.38%
2.3 Liquidity
GUD has a Current Ratio of 2.97. This indicates that GUD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GUD (2.97) is better than 72.73% of its industry peers.
GUD has a Quick Ratio of 2.06. This indicates that GUD is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 2.06, GUD is doing good in the industry, outperforming 75.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.97 | ||
| Quick Ratio | 2.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 168.75% over the past year.
The earnings per share for GUD have been decreasing by -13.46% on average. This is quite bad
The Revenue has grown by 12.21% in the past year. This is quite good.
Measured over the past years, GUD shows a very strong growth in Revenue. The Revenue has been growing by 50.87% on average per year.
EPS 1Y (TTM)168.75%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%150%
Revenue 1Y (TTM)12.21%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%2.66%
3.2 Future
The Earnings Per Share is expected to grow by 47.93% on average over the next years. This is a very strong growth
Based on estimates for the next years, GUD will show a quite strong growth in Revenue. The Revenue will grow by 9.23% on average per year.
EPS Next Y13.52%
EPS Next 2Y29.64%
EPS Next 3Y17.35%
EPS Next 5Y47.93%
Revenue Next Year9.9%
Revenue Next 2Y10.12%
Revenue Next 3Y7.13%
Revenue Next 5Y9.23%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 55.00, which means the current valuation is very expensive for GUD.
Based on the Price/Earnings ratio, GUD is valued a bit cheaper than 75.76% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.54, GUD is valued quite expensively.
The Price/Forward Earnings ratio is 72.00, which means the current valuation is very expensive for GUD.
Based on the Price/Forward Earnings ratio, GUD is valued a bit cheaper than the industry average as 69.70% of the companies are valued more expensively.
GUD is valuated expensively when we compare the Price/Forward Earnings ratio to 36.44, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55 | ||
| Fwd PE | 72 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GUD is valued a bit cheaper than 78.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 9.12 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
GUD's earnings are expected to grow with 17.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.07
PEG (5Y)N/A
EPS Next 2Y29.64%
EPS Next 3Y17.35%
5. Dividend
5.1 Amount
No dividends for GUD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:GUD (7/18/2025, 7:00:00 PM)
6.05
-0.16 (-2.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners10.02%
Inst Owner ChangeN/A
Ins Owners1.85%
Ins Owner ChangeN/A
Market Cap602.76M
Analysts78.18
Price Target7.72 (27.6%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)413.66%
Min EPS beat(2)365.93%
Max EPS beat(2)461.4%
EPS beat(4)2
Avg EPS beat(4)132.08%
Min EPS beat(4)-199.01%
Max EPS beat(4)461.4%
EPS beat(8)4
Avg EPS beat(8)-95.81%
EPS beat(12)7
Avg EPS beat(12)-39.29%
EPS beat(16)8
Avg EPS beat(16)-307.68%
Revenue beat(2)2
Avg Revenue beat(2)4.98%
Min Revenue beat(2)0.88%
Max Revenue beat(2)9.08%
Revenue beat(4)4
Avg Revenue beat(4)4.99%
Min Revenue beat(4)0.88%
Max Revenue beat(4)9.08%
Revenue beat(8)7
Avg Revenue beat(8)4.9%
Revenue beat(12)11
Avg Revenue beat(12)9.21%
Revenue beat(16)14
Avg Revenue beat(16)10.57%
PT rev (1m)0.1%
PT rev (3m)0.1%
EPS NQ rev (1m)-22.85%
EPS NQ rev (3m)-26.53%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-0.49%
Revenue NQ rev (3m)-2.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55 | ||
| Fwd PE | 72 | ||
| P/S | 1.62 | ||
| P/FCF | N/A | ||
| P/OCF | 66.46 | ||
| P/B | 0.76 | ||
| P/tB | 1.39 | ||
| EV/EBITDA | 9.12 |
EPS(TTM)0.11
EY1.82%
EPS(NY)0.08
Fwd EY1.39%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.09
OCFY1.5%
SpS3.74
BVpS7.98
TBVpS4.34
PEG (NY)4.07
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.1% | ||
| ROE | 1.39% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 2.97% | ||
| GM | 44.95% | ||
| FCFM | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score6
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 46.41% | ||
| Cap/Sales | 6.49% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 18.42% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.97 | ||
| Quick Ratio | 2.06 | ||
| Altman-Z | 2.68 |
F-Score6
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.75%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%150%
EPS Next Y13.52%
EPS Next 2Y29.64%
EPS Next 3Y17.35%
EPS Next 5Y47.93%
Revenue 1Y (TTM)12.21%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%2.66%
Revenue Next Year9.9%
Revenue Next 2Y10.12%
Revenue Next 3Y7.13%
Revenue Next 5Y9.23%
EBIT growth 1Y-220.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year371.57%
EBIT Next 3Y73.66%
EBIT Next 5Y52.72%
FCF growth 1Y-653.06%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y-71.04%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%